ECU Health enhances heart care with two new technologies
GREENVILLE, N.C. (WNCT) — The ECU Health Medical Center is expanding heart care with two new technologies for transcatheter tricuspid valve replacement.
The new technologies are EVOQUE™, a first-of-its-kind transcatheter tricuspid valve replacement, and TriClip G4™, a minimally invasive clip procedure designed to reduce tricuspid valve leakage. With these new technologies, patients who were previously ineligible for surgery, will now be provided symptom relief and improved quality of life.
'These new procedures represent a major advancement in the treatment of tricuspid valve regurgitation, offering hope to patients who previously had limited options,' Section Chief, Interventional Cardiology, Director, Cardiac Catheterization Lab, East Carolina Heart Institute, Dr. Paul Mahoney said. 'With the EVOQUE valve replacement and the TriClip G4, we can now provide effective, minimally invasive solutions that reduce symptoms and improve heart function without the need for open-heart surgery. This is a significant step forward in improving outcomes and quality of life for patients with TR.'
With treatment options being limited, these new technologies will allow patients to have access to innovative and minimally invasive options that can help to improve heart function and overall well-being.
'It is critical that patients in eastern North Carolina have access to the latest innovations in heart care close to home, so they do not have to travel far for cutting-edge treatment options,' said Dr. John Catanzaro, John 'Jack' Rose Distinguished Professor and Chief of the Division of Cardiology at the Brody School of Medicine at East Carolina University, and Director of the East Carolina Heart Institute at ECU Health Medical Center. 'Our commitment to bringing the most advanced cardiac treatments to this region ensures that patients receive high-quality, life-changing care without unnecessary delays or burdens. I am proud of our heart and vascular care teams who continue to advocate for patients in our region and ensure they receive world-class treatment right here at ECU Health.'
To learn more about ECU Health Heart & Vascular Care, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
ECU Health and Food Lion Feeds to offer free summer meals for kids
GREENVILLE, N.C. (WNCT) — ECU Health is partnering with Food Lion Feeds to provide summer meals for children and teens. Starting today, Wednesday, June 11, free meals are available Monday through Thursday at their different meal sites in Greenville, Ahoskie, Bethel, and Tarboro. They were at York Memorial AME Zion Church in Greenville today. 'We understand and we know that children, some children, don't have access to food once they leave the school during the summer,' Associate Minister at York Memorial AME Zion Church in Greenville, Janie Rouse, said. 'You know, they no longer have breakfast or lunch. And we're excited about offering them a lunch during the summer.' In 2024, 3,502 meals were served across the East. 'Our previous years, we have seen a lot of children as well as other community members come to our sites,' Community Health Project Consultant at ECU Health Alexis Connell said. 'Thankfully, this year we were able to expand to a four-site and in the future we hope to continue to expand to different sites in our community.' Meals will be available until food runs out each day at the following locations: Greenville: English Chapel Free Will Baptist Church – 11:30 a.m. to 1 p.m., Monday-Friday from June 10 to Aug. 23. The location will be closed July 22-26. Ahoskie: Calvary Missionary Baptist Church – 11:30 a.m. to 1 p.m., Monday-Friday from June 10 to Aug. 23. The location will be closed June 19 and July 4-5. Bethel: Bethel Youth Activity Center – 11:30 a.m. to 1 p.m., Monday-Thursday from June 17 to July 17. The location will be closed July 3-7. No registration is required. For more information about the ECU Health Summer Meal Program, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
Topeka's KMC Dermatology Is First in Kansas to Offer Nonsurgical GentleCure™ Treatment Option for Common Skin Cancer
BURR RIDGE, Ill., June 11, 2025 /PRNewswire/ -- SkinCure Oncology, the industry leader in providing a comprehensive cancer center model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer (NMSC), presented to dermatology patients and professionals as the GentleCure Experience™, today announced its first availability in Kansas at an event at Topeka's KMC Dermatology. Image-Guided SRT is the only treatment for nonmelanoma skin cancer (basal and squamous cell carcinoma) that uses ultrasound imaging to help clinicians direct low-level x-rays to targeted areas of the skin, killing cancer cells. For patients treated with Image-Guided SRT, the cure rate (freedom from recurrence at six years) has been shown to be greater than 99 percent, with researchers reporting that for appropriately selected early-stage nonmelanoma skin cancers, Image-Guided SRT is a clinically equivalent alternative to Mohs surgery and statistically significant in superiority to non-Image-Guided SRT. Dr. Joseph Gadzia of KMC Derm noted, "More than 26,000 individuals in Kansas are expected to be diagnosed with nonmelanoma skin cancer this year. We know that sun exposure is the main cause of this type of cancer but there are other factors as well. For those who have been diagnosed with nonmelanoma skin cancer, we now offer a nonsurgical treatment option which we call the GentleCure Experience, and we are proud to be the first practice in the state to offer it." Dr. Gadzia also added, "While most common skin cancers have been treated with Mohs surgery, this newer treatment option achieves close to the same success rate with no surgery, no surgical scarring, and no bleeding. As of this past April, more than 100,000 patients have been successfully treated with Image-Guided SRT in the United States." Other speakers included Dr. Shekhar Challa; U.S. Senator Roger Marshall via video; Topeka Mayor Michael Padilla; Aaron Mays, Chairman of the Shawnee County Board of Commissioners; and John Mugler, District Director, Office of Senator Marshall. In addition, Kansas Governor Laura Kelly issued a gubernatorial proclamation declaring June 8 – 14 "Kansas Nonmelanoma Skin Cancer Awareness Week," noting that KMC Dermatology is the first practice in the state of Kansas to offer Image-Guided SRT. Kerwin Brandt, chief executive officer of Chicago-based SkinCure Oncology, said, "We are delighted to partner with KMC Dermatology to offer this highly effective, noninvasive treatment option for their patients. It is critical that patients everywhere have the choice of treating their nonmelanoma skin cancer without surgery." About SkinCure OncologySkinCure Oncology is the industry leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT), the most advanced nonsurgical treatment for common skin cancer. The company partners with quality-focused dermatologists, Mohs surgeons and other physicians to bring cancer center-level radiation therapy treatment to private practices. Presented to patients as the GentleCure Experience™, Image-Guided SRT is available from some 500 physicians nationwide, with more than 100,000 patients having been treated. Learn more about the company at and visit for helpful consumer and patient information. Media Contact:Matt RussellRussell Public Communications520-232-9840mrussell@ View original content to download multimedia: SOURCE SkinCure Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
